To systematically evaluate the effectiveness and safety of heat-sensitive moxibustion (HSM) on asthma.
INTRODUCTION
The incidence of asthma (a chronic inflammatory disease in the airway involving many types of cells) is increasing worldwide. According to the global initiative for asthma (GINA) issued in 2008, about 300 million people have asthma and 180 000 people die due to asthma each year. 1, 2 The incidence of asthma in Western European countries has doubled in the past decade. It has been estimated that by 2025 the number of individuals with asthma will increase by 100-150 million worldwide. 3 Therefore, improving the prevention and treatment of asthma and controlling its symptoms has become a public-health issue worldwide. The pathogenesis of asthma is very complex. 4 Asthma is treated mainly with beta-2 adrenoceptor agonists and glucocorticoid hormones, but long-term use of such medications can cause side effects. 5 Therefore, the search for a therapy with better, stable and sustainable curative effects and with minor toxic side-effects has become a key issue in the prevention and treatment of asthma. Acupuncture-moxibustion has been used for a considerable time in China to treat asthma. Its unique curative effect and safety have been affirmed by researchers. Several studies have suggested that the mechanism of acupuncture-moxibustion against asthma is mainly through: improvement of ventilation; control of inflammatory reactions; regulation of immune functions; and adjustment of the nerve-endocrine network. [4] [5] [6] Moxibustion has been shown to reduce levels of immunoglobulin-E and the soluble interleukin-2 receptor in serum and enhance the contents of T3, T4, T8, T4/ T8 and natural-killer cells. 7 Therefore, the anti-asthma effects of moxibustion therapies [e.g., heat-sensitive moxibustion (HSM), crude-herb moxibustion, suppurative moxibustion, warm-suspended moxibustion] have become the foci of research. In recent years, HSM has shown considerable clinical effectiveness. 8 Systematic evaluation of the clinical trials that have employed HSM to treat asthma is lacking, a gap in knowledge that we have addressed in the present study.
MATERIALS AND METHODS

Inclusion criteria for articles
We included articles that were reports of randomized controlled trials (RCTs) irrespective of whether they were blinded or not. Articles could be written in Chinese or English. The targets of research were male or female patients aged >15 years and the source of these patients. Explicit diagnostic standards were based on the Guide for Preventing and Treating Bronchial Asthma issued by the Asthma group (respiratory disease branch) of the China Medical Association 1 and GINA. 9 HSM had to have been used in the trial group, and Western Medicines or Chinese drugs used in the control group. The outcome indices were the: Asthma Control Test (ACT); frequency of asthma attacks; St George's Respiratory Questionnaire (SGRQ); Traditional Chinese Medicine (TCM) score of asthma symptoms; pulmonary function [forced expiratory volume in one second (FEV1), peak expiratory flow (PEF), FEV1/forced vital capacity (FVC), maximal mid-expiratory flow (MMEF)]; effective rate(defined as more than 30% reduction of asthma attack frequenc by year according to the guiding principle of new drug of TCM); controlled rate (defined as the rate of "controlled"and "partly controlled " in GINA, described in Table 1 ); and adverse reactions.
Exclusion criteria for articles
We did not include articles that: were repeatedly retrieved or reissued; based on treatment with HSM and other therapies; included patients with other serious chronic diseases (e.g., diabetes, chronic obstructive diseases of the lung). The search terms in Chinese were "heat-sensitive moxibustion" and "asthma", whereas those in English were "heat-moxibustion" and "asthma". All searches were carried out until 30 April 2013.
Retrieval policy for articles
Method of evaluation
Data extraction: two evaluators read the titles and abstracts of articles independently. They excluded RCTs that obviously did not conform to the inclusion criteria and read the full-text of RCTs that might. Each (a) method of randomized distribution; (b) concealment of the distribution plan; (c) blinding method for the targets of research, practitioners of the therapeutic plan, and those measuring outcomes; (d) wholeness of consequent data; (e) result of research into selective reports; and (f) other sources of deviation. Each evaluator checked the choices of the other evaluator. Disagreements were settled by consensus. If consensus could not be reached, a third evaluator made the final decision.
Statistical analyses
RevMan v5.0.20 10 provided by Cochrane Coordination Net was used to carry out Meta-analysis. A heterogeneous test was conducted among studies. With P<0.1 as the test standard, if statistic heterogeneity among studies was absent, a fixed-effect model was used; if statistic heterogeneity among studies was present, the source of heterogeneity was found. If there was no clinical or methodological heterogeneity, a randomized-effect model was used to carry out combined analyses. The weighted mean difference (WMD) or standardized mean difference was used for continuous variables. Relative risk (RR) was used for categorical variables. Both effects were expressed with a 95% confidence interval (CI). P≤0.05 was considered significant. Descriptive analyses were carried out only for obvious clinical heterogeneity among studies. Sensitivity analyses were used to test the stability of the results if necessary.
RESULTS
Search results
Among the preliminarily selected articles in Chinese, three were theses issued at conferences, 31 theses were for doctorates, and 64 theses were published in periodicals. Finally, through screening, 14 articles involving 637 cases were selected (Figure 1 ).
Characteristics of research
Type of research: all the included studies were single-center RCTs and were shown in Table 2 . Targets of research: the study cohorts comprised outpatients or inpatients. All the included studies adopted the diagnostic standard set in the Guide for Preventing and Treating Bronchial Asthma. All but two studies detailed the inclusion and exclusion criteria. 11, 13 Eight studies detailed the criteria for rejection and suspension. 12, 14, [15] [16] [17] [22] [23] [24] Intervention measures: comparisons were made among three groups in one study, 11 among four groups in another study 12 and between two groups in the remainder of the studies. HSM was used in the trial group in all studies. Seretide was used in the control group of 12 RCTs. 11, [13] [14] [15] [17] [18] [19] [20] [21] [22] [23] [24] Changdi was used in the control group of one trial. Acupoint application was used in the control group of 1 trial. 12 Measurement indices: indices of pulmonary function were used in 13 studies. 11, [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] The ACT score was used in 10 trials. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] The effective rate was used in eight studies [12] [13] [14] [17] [18] [19] [20] [21] The controlled rate was used in 11 trials. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] 24 The SGRQ was used in one study. 15 The TCM score of asthma symptoms was used in three trials. 15, 22, 24 Adverse reactions were reported in two studies.
18,24
Quality of included RCTs
Most of the included RCTs were of high quality. Only two trials did not employ a standardized method of randomization. 11, 12 One trial used a digital method for randomization, 15 and the remainder adopted a central method of randomization. None of the trials used a distribution-concealing method. Four studies used a single blinding method for evaluators. 15, 18, 19, 22 Twelve trials provided detailed baseline data, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] and the remainder only mentioned baseline conditions and comparability. Two trials reported the conditions under which follow-up visits were carried out 20, 22 The risk of bias in the included RCTs is shown in Figure 2 .
HSM vs Western Medicine
Effective rate of controlling asthma: of the RCTs that compared HSM and Western Medicine, nine used the Notes: Liang Chao 2010 had three groups and Zhang Yuanbing 2012 had four groups. According to the aim of this research, only two groups were used. The trial group were given heat-sensitive mosibustion in all included studies; The treatment course was 3 months in all trials. ACT: asthma control test; SGRQ: St George's respiratory questionnaire; FEV1: forced expiratory volume in one second; PEF: peak expiratory flow; FVC: forced vital capacity; MMEF: maximal mid-expiratory flow; TCM: Tradtional Chinese Medicine; RCT: randomized controlled trial.
Included trial
Liang C et al 2010 11 Zhang YB et al 2012 12 Song NC et al 2012 13 Liang C et al 2010 14 OY BS et al 2011 15 Nie H 2011 16 Yang K 2010 17 Ma HJ 2011 18 Liao Y 2010 19 Zuo TP 2010 20 Lu YX 2010 21 Wu YJ 2010 ACT score, effective rate, controlled rate effective rate transformed from the ACT score [13] [14] [15] [16] [17] [18] 20, 22, 24 ( Figure 3 ). Meta-analysis showed no significant difference between the two groups after 3-month treatment [RR=1.01; 95% CI (0.92, 1.12)] and after 6-month follow-up [RR=1.12; 95% CI (0.93, 1.36)].
ACT score of asthma symptoms
In the eight trials that used the ACT score of asthma symptoms, 13, 15, 17, [18] [19] [20] [21] 24 Meta-analysis showed no significant difference between the two groups after 3-month treatment [WMD=-1.54; 95% CI ( -3.54, 0.47)] and after 6-month follow-up [WMD=1.41; 95% CI (-0.48, 3.29)] (Figure 4 ).
Pulmonary function: FEV1
In the eight trials that measured FEV1 [14] [15] [16] [17] [18] [22] [23] [24] , Meta-analysis showed no significant between the two groups after 3-month treatment [WMD=-0.37; 95% CI ( -2.27, 1.54)] and after 6-month follow-up [WMD=2.33; 95% CI (-0.48, 5.14)] ( Figure 5 ).
Pulmonary function: PEF
In the six trials that measured PEF, [15] [16] [17] [18] [23] [24] Meta-analysis showed no significant difference between the two groups after 3-month treatment [WMD=-0.17; 95% CI ( -2.69, 2.34)] and after 6-month follow-up [WMD=-3.09; 95% CI (-14.01, 7.83)] (Figure 6 ). 
Pulmonary function: other indices
In the two trials that used other indices of pulmonary function, 15, 22 Meta-analysis showed that after 3-month treatment, there was no significant difference between the two groups with regard to MMEF [WMD=-1.30; 95% CI ( -3.52, 0.92)] and FEV1/FVC [WMD=-1.71; 95% CI (-3.33, 0.99)]. In these two trials, 15, 22 after 3-month treatment, there was no significant difference between the two groups in the TCM score of asthma symptoms [WMD=-0.37; 95% CI (-1.33, 0.59)].
HSM vs warm-suspended moxibustion
In the one study that focused on HSM vs warm-suspended moxibustion, there was no significant in FEV1 between the two groups 11, 17 after 3-month treatment [WMD=0.09; 95% CI (-0.31, 0.49)] but a significant difference was observed after 6-month follow-up [WMD=0.51; 0.10-0.92). There was no significant difference in PEF between the two groups 11, 17 after 3-month treatment [WMD=0.35; 95% CI ( -0.36, 1.06)] but a significant difference was noted after 
HSM vs acupoint application
In the one study that focused on HSM vs acupoint application, 12 after 3-month treatment, there was no significant difference in the effective rate between HSM and acupoint application (RR=0.68; 95% CI (0.42, 1.12)].
Adverse reactions
Adverse reactions were reported in 2 studies. Ma 18 reported that after 5-day treatment, one patient in the HSM group had asthma onset before leaving the trial and one patient in the Western Medicine group had medication-related chest tightness. Si 24 reported that after 2-day treatment, one patient in the HSM group had the onset of mild acute infection in the upper respiratory tract and, after treatment, he remained in the study. After 1-month treatment with Seretide, one patient in the Western Medicine group had a hoarse voice that was sometimes accompanied by a sore throat and white phlegm; after spraying the drug in the throat before rinsing the mouth, the symptoms improved and he remained in the study. Hence, Seretide could cause adverse reactions in the throat.
DISCUSSION
We systematically evaluated 14 RCTs involving 637 patients. Most trials were carried out with small cohorts and had low methodological quality. All but two RCTs used central or digital methods of randomization. No trial described a distribution-concealing method. Four trials adopted a blinding method for evaluators. Most trials provided detailed baseline data. Overall, the low quality of included trials would lead to clinical heterogeneity and bias, so evaluations should be treated with caution. RCTs are used to investigate the effects of interventions. Randomization is one of the three important features (along with the method of blinding, and having controls) in designing a RCT. In a RCT, randomization should comprise at least four aspects: type of randomization method; order of randomized distribution; distribution-concealing method; and specific practitioners. The included RCTs described the randomization method, but a specific description of the randomization process (especially distribution-concealing measures and information on practitioners) was lacking. Estimating the minimum number of samples in a RCT is crucial. Too few samples will result in a lack of statistical power, whereas too many samples will consume manpower, resources and time. All the included RCTs had small cohorts and did not provide detailed information about the patients. The method of blinding has been the focus of discussion on RCTs of acupuncture-moxibustion. Acupuncture-moxibustion involves very skilful manipulation, and blinding subjects and practitioners (particularly between acupuncture-moxibustion and drugs) is very difficult. However, the method of blinding can be practiced on those in charge of evaluating outcome indices and data (i.e., they do not know which groups the patients are in). The included RCTs mostly used the blinding method on statisticians and study subjects, and the blinding method on the latter was different types of moxibustion. The baseline data in some of the RCTs were described in simple terms without giving specific statistical values. The present study showed that designers and practitioners of RCTs need to have much better basic knowledge on RCTs. Smaller pilot trials should be carried out and sample contents calculated before implementation of the larger RCT. RCTs of acupuncture-moxibus- tion should be reported according to the internationally accepted CONSORT and STRICTA 25, 26 criteria to enhance the quality of clinical research into the use of acupuncture-moxibustion against asthma. We wished to evaluate the clinical effectiveness of HSM on asthma. HSM compared with the conventional Western Medicine Seretide was used in 12 RCTs and Meta-analysis showed no significant differences in the effective rate, parameters of pulmonary function, and ACT score between the two groups. In Western Medicine, glucocorticoid hormones are used to dampen inflammation and beta-2 adrenoceptor agonists to relax bronchial smooth muscle to alleviate spasms, thereby resolving the symptoms of asthma. The included RCTs showed no significant differences in curative effects between HSM and Seretide, but could better-designed RCTs be developed to ascertain differences in curative effects between these two therapies? If it can be confirmed that HSM is not inferior to Seretide in terms of curative effects, HSM could replace Seretide in the treatment of chronic asthma. With regard to safety, inhaling Seretide will probable cause adverse reactions in the mouth and throat. Hence, infants, elderly subjects and those with poor pulmonary function will encounter difficulties in inhaling Seretide into the lower respiratory tract, resulting in suboptimal effects. The included RCTs showed that HSM had fewer adverse reactions and better safety than Seretide. In one RCT, there was a significant difference in FEV1 and PEF between HSM and suspended moxibustion after 6-month follow-up and no significant difference after 3-month treatment. HSM did not show superiority to acupoint application in terms of curative effects. HSM did not show superiority to conventional Western Medicine and acupoint application in terms of curative effects, and may be superior to warm-suspended moxibustion with regard to long-term curative effects. Because of low quality of the included RCTs, this conclusion must be bolstered with higher-quality RCTs. We suggest that in future studies, a strict and practicable multi-center RCT with a large patient cohort should be designed to assess the effectiveness of HSM on asthma.
